drugset / Trial / NCT00460655

Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity

NCT00460655 ↗

Phase 3 Completed 120 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a study to confirm the superior efficacy of GSK1358820 over placebo in patients with equinus deformity associated with post-stroke lower limb spasticity using the Modified Ashworth Scale (MAS) ankle score.

Timeline

Start
2007-05
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator GSK1358820 Protein / enzyme biologic 300 iu —

Indications